Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice

The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis

(2018) Masayuki Yamamoto et al.   PHYSIOLOGICAL REVIEWS

Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

(2017) Annika S. Axelsson et al.   Science Translational Medicine

Nrf2 Improves Leptin and Insulin Resistance Provoked by Hypothalamic Oxidative Stress

(2017) Yoko Yagishita et al.   Cell Reports

Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet

(2016) Stephen L. Slocum et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Nrf2-Mediated Regulation of Skeletal Muscle Glycogen Metabolism

(2016) Akira Uruno et al.   MOLECULAR AND CELLULAR BIOLOGY

Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription

(2016) Eri H. Kobayashi et al.   Nature Communications

The Keap1–Nrf2 system and diabetes mellitus

(2015) Akira Uruno et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Whole-BodyIn VivoMonitoring of Inflammatory Diseases Exploiting Human Interleukin 6-Luciferase Transgenic Mice

(2015) Makiko Hayashi et al.   MOLECULAR AND CELLULAR BIOLOGY

The Emerging Global Epidemic of Type 1 Diabetes

(2013) Jaakko Tuomilehto   Current Diabetes Reports

Nrf2 Protects Pancreatic  -Cells From Oxidative and Nitrosative Stress in Diabetic Model Mice

(2013) Y. Yagishita et al.   DIABETES

Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice

(2013) Bin Li et al.   EXPERIMENTAL NEUROLOGY

Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response

(2013) Tao Jiang et al.   KIDNEY INTERNATIONAL

The Keap1-Nrf2 System Prevents Onset of Diabetes Mellitus

(2013) A. Uruno et al.   MOLECULAR AND CELLULAR BIOLOGY

Bioluminescence Imaging Reveals Dynamics of Beta Cell Loss in the Non-Obese Diabetic (NOD) Mouse Model

(2013) John Virostko et al.   PLoS One

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy

(2011) Hongting Zheng et al.   DIABETES

Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution

(2011) Keiko Taguchi et al.   GENES TO CELLS

The Keap1–Nrf2 system as an in vivo sensor for electrophiles

(2011) Akira Uruno et al.   NITRIC OXIDE-BIOLOGY AND CHEMISTRY

Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice

(2010) C. J. Wruck et al.   ANNALS OF THE RHEUMATIC DISEASES

Genetic Analysis of Cytoprotective Functions Supported by Graded Expression of Keap1

(2010) K. Taguchi et al.   MOLECULAR AND CELLULAR BIOLOGY

Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet☆

(2010) Yu-Kun Jennifer Zhang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway

(2008) Wen Lin et al.   BIOCHEMICAL PHARMACOLOGY

Sulforaphane protects against cytokine- and streptozotocin-induced β-cell damage by suppressing the NF-κB pathway

(2008) Mi-Young Song et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY